A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)
Latest Information Update: 02 Jun 2024
At a glance
- Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Paclitaxel (Primary)
- Indications Small cell lung cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms TAXIO
- 18 Dec 2023 Planned End Date changed from 1 Dec 2027 to 1 Feb 2028.
- 18 Dec 2023 Planned primary completion date changed from 1 Nov 2025 to 1 Feb 2026.
- 18 Dec 2023 Status changed from not yet recruiting to recruiting.